CC0 1.0 Universal Public Domain Dedicationhttps://creativecommons.org/publicdomain/zero/1.0/
License information was derived automatically
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with an extremely poor prognosis, predominantly due to chemotherapy resistance and numerous somatic mutations. Consequently, PDAC is a prime candidate for the use of sequencing to identify causative mutations, facilitating subsequent administration of targeted therapy. In a feasibility study, we retrospectively assessed the therapeutic recommendations of a novel, evidence-based software that analyzes Next-generation sequencing (NGS) data using a large panel of pharmacogenomic biomarkers for efficacy and toxicity. Tissue from 14 patients with PDAC was sequenced using NGS with a 620 gene panel. FASTQ files were fed into the TreatmentMAP software. The results were compared with chemotherapy in the patients, including all side effects. No changes in therapy were made. Known driver mutations for PDAC were confirmed, e.g. KRAS, TP53. Software analysis revealed positive biomarkers for predicted effective and ineffective treatments in all patients. At least one biomarker associated with increased toxicity could be detected in all patients. Patients had been receiving one of the currently approved chemotherapy agents. In two patients, toxicity could have been correctly predicted by the software analysis. Results suggest NGS, in combination with an evidence-based software, could be conducted within a two-week period - thus being feasible for clinical routine. Therapy recommendations were principally off-label use. Based on the predominant KRAS mutations, other drugs were predicted to be ineffective. The pharmacogenomic biomarkers indicative of increased toxicity could be retrospectively linked to reported negative side effects in the respective patients. Finally, the occurrence of somatic and germline mutations in cancer syndrome-associated genes is noteworthy, despite a high frequency of these particular variants in the background population. These results suggest software-analysis of NGS data provides evidence-based information on effective, ineffective, and toxic drugs, potentially forming the basis for precision cancer medicine in PDAC.
https://www.databridgemarketresearch.com/privacy-policyhttps://www.databridgemarketresearch.com/privacy-policy
Report Metric |
Details |
Forecast Period |
2023 to 2030 |
Base Year |
2022 |
Historic Years |
2021 (Customizable to 2015 - 2020) |
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
Segments Covered |
Imaging Type (2D Imaging, 3D Imaging, 4D Imaging), Application (Dental Applications, Orthopedic Applications, Cardiology Applications, Obstetrics and Gynecology Applications, Mammography Applications, Urology and Nephrology Applications), End-User (Hospitals, Diagnostic Centers) |
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
Market Players Covered |
Koninklijke Philips N.V. (Netherlands), RamSoft, Inc. (Canada), InHealth Group (U.K.), Radiology Reports online (U.S.), Siemens (Germany), Sonic Healthcare Limited (Australia), RadNet, Inc. (U.S.), General Electric (U.S.), Akumin Inc. (U.S.), Hologic Inc. (U.S.), Shimadzu Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), CANON MEDICAL SYSTEMS CORPORATION (Japan), Carl Zeiss Ag (Germany), FUJIFILM Corporation (Japan), Hitachi, Ltd. (Japan), MEDNAX Services, Inc. (U.S.), Carestream Health (U.S), Teleradiology Solutions (U.S.), UNILABS (Switzerland), ONRAD, Inc. (U.S.) |
Market Opportunities |
|
This database allows you to search the CDRH's database information on medical devices which may have malfunctioned or caused a death or serious injury during the years 1992 through 1996.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
A 100,000-patient database that contains in total 100,000 virtual patients, 361,760 admissions, and 107,535,387 lab observations.
https://market.us/privacy-policy/https://market.us/privacy-policy/
The Global Medical Carts Market size is expected to be worth around USD 7.1 Billion by 2033, from USD 2.1 Billion in 2023, growing at a CAGR of 12.7% during the forecast period from 2024 to 2033.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Project Overview: The goal of this project is to develop a computer vision system that can accurately classify medication blisters as either full or empty. This system will aid in automating the verification process of medication blister packs, ensuring the correct dispensing of medications in healthcare settings. By leveraging machine learning techniques and image analysis algorithms, the system will be trained on a dataset of labeled images to achieve high accuracy in blister classification.
Class Types:
Full Blister: This class represents medication blisters that contain the intended number of pills or capsules. Images labeled as "full" will be used as positive examples during the training phase.
Empty Blister: This class represents medication blisters that do not contain any pills or capsules. Images labeled as "empty" will serve as negative examples during training.
This statistic represents the breakdown of French people giving up a treatment prescribed by a conventional doctor to replace it by an alternative medicine treatment in 2019. It shows that the majority of respondents, 74 percent, had not given up following a treatment prescribed by a doctor to replace it with an alternative medicine treatment.
Alternative medicine, also called complementary or integrative medicine among others, designates therapeutic practices residing outside classical medical science which originated from oriental, ancestral or innovative traditions. Among those alternative medicines, we can for example find acupuncture (from Chinese medicine), Ayurvedic medicine, herbal medicine, osteopathy or homeopathy.
The UMLS integrates and distributes key terminology, classification and coding standards, and associated resources to promote creation of more effective and interoperable biomedical information systems and services, including electronic health records.
https://www.futuremarketinsights.com/privacy-policyhttps://www.futuremarketinsights.com/privacy-policy
The global medical terahertz technology market is valued at US$ 135.29 Million in 2022 and is projected to grow at a CAGR of 17.1% during the forecast period, reaching a value of US$ 768.05 Million by 2032.
Attribute | Details |
---|---|
Medical Terahertz Technology Market Size Value in 2022 | US$ 135.29 Million |
Medical Terahertz Technology Market Forecast Value in 2032 | US$ 768.05 Million |
Medical Terahertz Technology Market CAGR Global Growth Rate (2022 to 2032) | 17.1% |
Scope of Report
Attribute | Details |
---|---|
Forecast Period | 2022 to 2032 |
Historical Data Available for | 2018 to 2022 |
Market Analysis | US$ Billion for Value and MT for Volume |
Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa |
Key Countries Covered | USA, Canada, Brazil, Mexico, Chile, Peru, Germany, United Kingdom., Spain, Italy, France, Russia, Poland, China, India, Japan, Australia, New Zealand, GCC Countries, North Africa, South Africa, and Turkey |
Key Segments Covered |
|
Key Companies Profiled |
|
Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
Customization & Pricing | Available upon Request |
This dataset was created by rjain777
https://www.technavio.com/content/privacy-noticehttps://www.technavio.com/content/privacy-notice
The medical image analysis software market has the potential to grow by USD 1.53 billion during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 7.90%.
This medical image analysis software market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers market segmentation by type (standalone and integrated) and geography (North America, APAC, Europe, South America, and MEA). The medical image analysis software market report also offers information on several market vendors, including Agfa-Gevaert NV, AnalyzeDirect Inc., AQUILAB SAS, Carestream Health Inc., Esaote SpA, General Electric Co., International Business Machines Corp., Koninklijke Philips NV, Mirada Medical Ltd., and Siemens AG among others.
What will the Medical Image Analysis Software Market Size be in 2021?
Browse TOC and LoE with selected illustrations and example pages of Medical Image Analysis Software Market
Get Your FREE Sample Now!
Medical Image Analysis Software Market: Key Drivers and Trends
Based on our research output, there has been a positive impact on the market growth during and post COVID-19 era. The advances in the medical imaging field is notably driving the medical image analysis software market growth, although factors such as growing concerns regarding data privacy and security may impede market growth. To unlock information on the key market drivers and the COVID-19 pandemic impact on the medical image analysis software industry get your FREE report sample now.
The emergence of advanced technologies in medical imaging is a major factor driving the demand for medical imaging systems.
With advanced research and technological evolution, medical imaging has seen numerous advances in technology.
Open and portable MRIs, big data and analytics, and 3D technologies in diagnostic radiology are some of the latest advances that have increased the capabilities of medical imaging systems.
Digital mammography has revolutionized breast cancer screening by providing greater detail and can generate results that are similar to conventional mammograms but without using film and X-rays.
From the use of big data in medical imaging to the possibilities of 3D imaging, these advances are changing the future of medical imaging and leading to increased adoption of different medical imaging techniques.
As the occurrence of chronic diseases increases in the population worldwide, there will be an increased use of medical imaging techniques and high demand for image analysis for improved diagnoses.
The growing prevalence of chronic diseases and generally incurable conditions, such as cancer, cardiovascular conditions, diabetes, and asthma, is responsible for the increase in demand for medical imaging systems.
Post-imaging analysis using advanced image analysis software helps in the early detection of chronic diseases and assesses the effectiveness of therapy on patients.
Medical imaging technology plays a major role in addressing chronic health concerns, as it helps in focusing on preventative health.
Diagnostic imaging plays a crucial role in the early detection of chronic diseases and in monitoring disease progression.
This medical image analysis software market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. Get detailed insights on the trends and challenges, which will help companies evaluate and develop growth strategies.
Who are the Major Medical Image Analysis Software Market Vendors?
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
Agfa-Gevaert NV
AnalyzeDirect Inc.
AQUILAB SAS
Carestream Health Inc.
Esaote SpA
General Electric Co.
International Business Machines Corp.
Koninklijke Philips NV
Mirada Medical Ltd.
Siemens AG
The medical image analysis software market is fragmented and the vendors are deploying growth strategies such as creating awareness about the benefits of using medical image analysis software to compete in the market. Click here to uncover other successful business strategies deployed by the vendors.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
Download a free sample of the medical image analysis software market forecast report for insights on complete key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Which are the Key Regions for Medical Image Analysis Software
This statistic shows forecasts for the global biomarker market in 2024 and 2029. By the year 2029, the market for biomarker technologies is expected to increase up to 88 billion U.S. dollars. Biomarkers are biomolecules present in blood, other bodily fluids, or tissues indicating either a normal or abnormal physiological process, or the presence of a condition or illness.
The prescription center is an electronic database for issuing and processing prescriptions (for medicines, baby foods, medical devices).
https://www.persistencemarketresearch.com/privacy-policy.asphttps://www.persistencemarketresearch.com/privacy-policy.asp
The global Asia Medical Imaging Informatics Market market size exceeded USD 5.15 billion in 2022 and is slated to register 15.5% CAGR between 2023 and 2033
The New England Journal of Medicine Abbreviation ISO4 - ResearchHelpDesk - The New England Journal of Medicine (NEJM) is the world’s leading medical journal and website. Published continuously for over 200 years, NEJM delivers high-quality, peer-reviewed research and interactive clinical content to physicians, educators, and the global medical community. Our mission is to bring physicians the best research and information at the intersection of biomedical science and clinical practice and to present this information in understandable and clinically useful formats that inform health care delivery and improve patient outcomes. To these ends, the NEJM editorial team employs rigorous: Editorial, peer, and statistical review processes to evaluate manuscripts for scientific accuracy, novelty, and importance. Policies and practices to ensure that authors disclose all relevant financial associations and that such associations in no way influence the content NEJM publishes. A truly global brand, NEJM keeps health care professionals at the leading edge of medical knowledge, helps them to gain broad understanding in their areas of interest, and provides valuable perspectives on the practice of medicine. Today, NEJM is the most widely read, cited, and influential general medical periodical in the world. More than 600,000 people from nearly every country read NEJM in print and online each week. Each year, NEJM receives more than 16,000 research and other submissions for consideration for publication. About 5% of original research submissions achieve publication by NEJM; more than half originate from outside the U.S. NEJM is cited more often in scientific literature than any other medical journal, and has the highest Journal Impact Factor (70.670) of all general medical journals (2018 Journal Citation Reports, Web of Science Group, 2019). NEJM is a Public Access Journal. All original research content is freely available on NEJM.org six months after the date of publication. In addition, qualifying low-income countries are granted free access to all articles on NEJM.org dating back to 1990. The editors may also make certain materials including articles on global health and of public health importance free to all readers immediately upon publication on NEJM.org
In order to facilitate public review and access, enrollment data published on the Open Data Portal is provided as promptly as possible after the end of each month or year, as applicable to the data set. Due to eligibility policies and operational processes, enrollment can vary slightly after publication. Please be aware of the point-in-time nature of the published data when comparing to other data published or shared by the Department of Social Services, as this data may vary slightly. As a general practice, for monthly data sets published on the Open Data Portal, DSS will continue to refresh the monthly enrollment data for three months, after which time it will remain static. For example, when March data is published the data in January and February will be refreshed. When April data is published, February and March data will be refreshed, but January will not change. This allows the Department to account for the most common enrollment variations in published data while also ensuring that data remains as stable as possible over time. In the event of a significant change in enrollment data, the Department may republish reports and will notate such republication dates and reasons accordingly. In March 2020, Connecticut opted to add a new Medicaid coverage group: the COVID-19 Testing Coverage for the Uninsured. Enrollment data on this limited-benefit Medicaid coverage group is being incorporated into Medicaid data effective January 1, 2021. Enrollment data for this coverage group prior to January 1, 2021, was listed under State Funded Medical. An historical accounting of enrollment of the specific coverage group starting in calendar year 2020 will also be published separately. The data represents number of active recipients who received benefits under a medical benefit plan in that calendar year. A recipient may have received benefits from multiple plans in the same year; if so that recipient will be included in multiple categories in this dataset (counted more than once.) For privacy considerations, a count of zero is used for counts less than five. NOTE: On April 22, 2019 the methodology for determining HUSKY A Newborn recipients changed, which caused an increase of recipients for that benefit starting in October 2016. We now count recipients recorded in the ImpaCT system as well as in the HIX system for that assistance type, instead using HIX exclusively. Also, the methodology for determining the address of the recipients changed: 1. The address of a recipient in the ImpaCT system is now correctly determined specific to that month instead of using the address of the most recent month. This resulted in some shuffling of the recipients among townships starting in October 2016. 2. If, in a given month, a recipient has benefit records in both the HIX system and in the ImpaCT system, the address of the recipient is now calculated as follows to resolve conflicts: Use the residential address in ImpaCT if it exists, else use the mailing address in ImpaCT if it exists, else use the address in HIX. This resulted in a reduction in counts for most townships starting in March 2017 because a single address is now used instead of two when the systems do not agree. NOTE: On February 14 2019, the enrollment counts for 2012-2015 across all programs were updated to account for an error in the data integration process. As a result, the count of the number of people served increased by 13% for 2012, 10% for 2013, 8% for 2014 and 4% for 2015. Counts for 2016, 2017 and 2018 remain unchanged. NOTE: On 11/30/2018 the counts were revised because of a change in the way active recipients were counted in one source system.
https://www.data.gov.uk/dataset/655d531b-21d9-428e-9b31-1ee30110d8c8/epidemiology-medical-statistics-unit-emsu-national-proficiency-testing-council-nptc#licence-infohttps://www.data.gov.uk/dataset/655d531b-21d9-428e-9b31-1ee30110d8c8/epidemiology-medical-statistics-unit-emsu-national-proficiency-testing-council-nptc#licence-info
Used for inputting, retention, retrieval and analysis of medical data collection on workers exposed to pesticides. Number of records in dataset – 85,900. Contains sensitive medical in confidence data and personal data.
https://fred.stlouisfed.org/legal/#copyright-public-domainhttps://fred.stlouisfed.org/legal/#copyright-public-domain
Graph and download economic data for Consumer Price Index for All Urban Consumers: Services Less Medical Care Services in U.S. City Average (CUUR0000SASL5) from Mar 1957 to Mar 2024 about medical, urban, consumer, services, CPI, inflation, price index, indexes, price, and USA.
CC0 1.0 Universal Public Domain Dedicationhttps://creativecommons.org/publicdomain/zero/1.0/
License information was derived automatically
All results of the primary interrupted time-series results evaluating targeted and total border closures that met the following criteria: 1) at least seven days of data is available before and after the intervention point, 2) for multiple intervention time series, at least seven days has passed since the last intervention point, and 3) for multiple sequential targeted border closures, the second (or third) intervention is observed to indicate an increase of at least 20% of the world’s population being targeted by the new border closures.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Number of medical condition transactions in Queensland by month and transaction type.
CC0 1.0 Universal Public Domain Dedicationhttps://creativecommons.org/publicdomain/zero/1.0/
License information was derived automatically
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with an extremely poor prognosis, predominantly due to chemotherapy resistance and numerous somatic mutations. Consequently, PDAC is a prime candidate for the use of sequencing to identify causative mutations, facilitating subsequent administration of targeted therapy. In a feasibility study, we retrospectively assessed the therapeutic recommendations of a novel, evidence-based software that analyzes Next-generation sequencing (NGS) data using a large panel of pharmacogenomic biomarkers for efficacy and toxicity. Tissue from 14 patients with PDAC was sequenced using NGS with a 620 gene panel. FASTQ files were fed into the TreatmentMAP software. The results were compared with chemotherapy in the patients, including all side effects. No changes in therapy were made. Known driver mutations for PDAC were confirmed, e.g. KRAS, TP53. Software analysis revealed positive biomarkers for predicted effective and ineffective treatments in all patients. At least one biomarker associated with increased toxicity could be detected in all patients. Patients had been receiving one of the currently approved chemotherapy agents. In two patients, toxicity could have been correctly predicted by the software analysis. Results suggest NGS, in combination with an evidence-based software, could be conducted within a two-week period - thus being feasible for clinical routine. Therapy recommendations were principally off-label use. Based on the predominant KRAS mutations, other drugs were predicted to be ineffective. The pharmacogenomic biomarkers indicative of increased toxicity could be retrospectively linked to reported negative side effects in the respective patients. Finally, the occurrence of somatic and germline mutations in cancer syndrome-associated genes is noteworthy, despite a high frequency of these particular variants in the background population. These results suggest software-analysis of NGS data provides evidence-based information on effective, ineffective, and toxic drugs, potentially forming the basis for precision cancer medicine in PDAC.